Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
1
|
pubmed:dateCreated |
1987-4-15
|
pubmed:abstractText |
From january 1982 to january 1986 we treated 23 pediatric patients who had non Hodgkin's lymphoma, with a new therapeutic protocol. This protocol is based on the LSA2 L2, modified during the induction phase with high-dose methotrexate and increasing of intrathecal therapy. Nineteen patients (83%) were in stages III and IV and the 47.4% were in stage IV. The distribution according to histology was: 10 Burkitt's undifferentiated lymphomas; 2 non-Burkitt's undifferentiated lymphomas; 5 lymphoblastic lymphomas convoluted-cells; 5 lymphoblastic lymphoma non-convoluted cells and 1 indeterminate lymphoma. The follow-up oscillated between 6 months and 4 years. The total survival rate is 82.6% with a 100% survival in stages I, II and III and 63.5% in stage IV. The survival according histology is 91.7% for undifferentiated lymphomas and 70% for lymphoblastic lymphomas; the actuarial survival rates in the two groups at 30 months are 87% and 55% respectively (p greater than 0.10). We concluded that adding high-dose methotrexate to the LSA2 L2 protocol improve the survival rate in undifferentiated lymphomas and in a less extent in lymphoblastic lymphomas, without significant toxicity. This new protocol is mainly indicated in undifferentiated and indeterminate non-Hodgkin's lymphomas.
|
pubmed:language |
spa
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Cyclophosphamide,
http://linkedlifedata.com/resource/pubmed/chemical/Daunorubicin,
http://linkedlifedata.com/resource/pubmed/chemical/Methotrexate,
http://linkedlifedata.com/resource/pubmed/chemical/Prednisone,
http://linkedlifedata.com/resource/pubmed/chemical/Vincristine
|
pubmed:status |
MEDLINE
|
pubmed:month |
Jan
|
pubmed:issn |
0302-4342
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
26
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
15-21
|
pubmed:dateRevised |
2006-11-15
|
pubmed:meshHeading |
pubmed-meshheading:3826937-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:3826937-Child,
pubmed-meshheading:3826937-Child, Preschool,
pubmed-meshheading:3826937-Cyclophosphamide,
pubmed-meshheading:3826937-Daunorubicin,
pubmed-meshheading:3826937-Female,
pubmed-meshheading:3826937-Humans,
pubmed-meshheading:3826937-Infant,
pubmed-meshheading:3826937-Lymphoma, Non-Hodgkin,
pubmed-meshheading:3826937-Male,
pubmed-meshheading:3826937-Methotrexate,
pubmed-meshheading:3826937-Prednisone,
pubmed-meshheading:3826937-Vincristine
|
pubmed:year |
1987
|
pubmed:articleTitle |
[Non-Hodgkin? lymphoma in childhood, preliminary results of the LSA2 L2 protocol modified by high-dose methotrexate].
|
pubmed:publicationType |
Journal Article,
English Abstract
|